When you're dealing with chronic allergies, asthma, or sinus problems, it can feel like you're navigating a confusing system. A group of medical experts just held a summit to try to clear a path forward. They gathered to establish priorities for research, education, and advocacy specifically for people with these chronic inflammatory respiratory conditions. The goal is to build a coordinated plan to improve care. It's important to know this was a planning meeting. No new treatments were tested, and no specific results about what works best were announced. The value here is in the focus—getting experts aligned on what to tackle next for patients who need better answers.
EUFOREA summit sets priorities for allergy and respiratory care research and advocacyWhat should doctors prioritize for allergy and asthma care? Experts just met to decide
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Note: This is a strategic priorities report, not a source of clinical evidence.
A report from a EUFOREA summit details the establishment of priorities for research, education, and advocacy in the field of allergy and respiratory care. The focus is on conditions including chronic rhinosinusitis, allergic rhinitis, asthma, and allergen immunotherapy, with a mention of pediatric considerations. The document is a position or consensus statement, not a clinical trial or observational study.
No specific study design, patient population, sample size, intervention, comparator, or clinical outcomes are reported. The main results section is empty, and no quantitative data on efficacy or effectiveness are provided. Safety and tolerability information, including adverse events and discontinuations, are also not reported.
Key limitations include the absence of any clinical data, patient demographics, or methodological details. The practice relevance and funding or conflicts of interest are not reported. This document serves solely to outline a strategic agenda for future work in this clinical area, offering no direct evidence to guide current patient management.
What this means for you:
Experts are mapping a better future for allergy and asthma care. View Original Abstract ↓
EUFOREA, the European Forum for Research and Education in Allergy and Airways diseases, is an international non-for-profit organisation of physicians, patients, and other stakeholders committed to the improvement of outcomes for patients suffering from chronic inflammatory respiratory conditions through collaborative research, education, and targeted advocacy. In February 2025, EUFOREA hosted its biennial summit in Brussels, convening expert panels, its Patient Advisory Board, and a range of leadership representatives. This event was pivotal in establishing the research, educational, and advocacy priorities for the subsequent 2-year period, coinciding with the organisation's 10th anniversary in April 2025. Building on its core competencies, EUFOREA advances evidence-based clinical tools and educational initiatives designed to narrow the gap between emerging science and routine care. In alignment with the objective of enhancing global healthcare standards, the specialists' panels of chronic rhinosinusitis and European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergic rhinitis, asthma, allergen immunotherapy, and paediatrics have devised and detailed a comprehensive range of initiatives that address significant unmet needs within the domains of allergy and respiratory care. This document presents a summary of EUFOREA's future objectives, aspirations, and strategy, providing a clear direction for the coming years. It serves as a valuable resource for individuals and organisations involved in both the allergy and the respiratory sectors, offering a comprehensive overview of the association's plans and initiatives.
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
FDA Approves Exdensur for Add-On Maintenance Treatment of Severe Eosinophilic Asthma
FDA approves new long-acting shot Exdensur for severe asthma.
FDA approved Exdensur (IL-5 antagonist) for add-on maintenance treatment of severe eosinophilic asthma in patients aged 12 years and older. …
The FDA approved Exdensur as an add-on treatment for severe asthma in people 12 and older. It is given as a shot every six months. This new …
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis
Immune Cells and Signaling Pathways Influence Bone Health in Osteoporosis
This narrative review synthesizes the role of CD8+ T cells and related cytokines like IFN-gamma, CCL5, and IL-33 in bone metabolism. The aut…
New research highlights how specific immune cells and signaling pathways may play a dual role in protecting or promoting bone loss in osteop…
E3 ubiquitin ligases modulate SARS-CoV-2 replication and immune evasion through targeted protein degradation mechanisms
SARS-CoV-2 uses host enzymes to hide from the immune system
This mini-review explores the role of E3 ubiquitin ligases in the context of SARS-CoV-2 infection. The authors synthesize how these enzymes …
New research shows how the virus hijacks specific proteins in our cells to replicate and dodge our body's natural defenses.
From Other Specialties
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…